Adding PD1 Inhibitor to Neoadjuvant Chemotherapy Significantly Increases the pCR Rate in High-Risk, Early-Stage ER-positive, HER2-negative Breast Cancer By Ogkologos - February 12, 2025 966 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 7FL and KEYNOTE-756 studies Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Olivia Newton-John Talks About Her Use Of Medical Cannabis During Cancer... May 28, 2019 Opportunity and mentorship: Our new PhD programme aiming to open-up academia... July 22, 2022 RANO and Modified RANO Criteria Demonstrate Similar Correlations Between PFS and... April 18, 2023 Adding Pembrolizumab to Chemotherapy Results in Improved PFS and OS in... November 25, 2024 Load more HOT NEWS I Received the COVID-19 Vaccine – Now What? Some Hormone Therapy Drugs For Breast Cancer Could Reduce Alzheimer’s Risk Combined MRI-directed and Standard Biopsy in Men With Elevated PSA and... Unusual or Nonreportable Results from Prenatal cfDNA-Sequencing Suggestive for an Occult...
